Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OGG1 | O15527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29708059 | 1.00 | ALDH1A1 (0.42) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL1744521 | 1.00 | ALDH1A1 (0.42) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL15726979 | 1.00 | ALDH1A1 (0.42) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL20305851 | 0.89 | ELANE (0.41) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL10208224 | 0.89 | ELANE (0.41) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL19685665 | 0.88 | CASP1 (0.45) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL18067130 | 0.88 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL19685663 | 0.88 | CASP1 (0.45) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL18067131 | 0.88 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTCASP1MRGPRX4 | |
| SCHEMBL1273006 | 0.87 | BTN3A1 (0.45) | ALDH1A1GAAELANEBTN3A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3447061-B1 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHORAMIDATE DERIVATIVE OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2021-05-04 | — | — | US | disclosed |
| CN-111909231-A | 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds | 努卡那有限公司 | 2020-11-10 | — | — | CN | disclosed |
| WO-2013044030-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-8399429-B2 | Uracyl cyclopropyl nucleotides | JANSSEN PRODUCTS, LP (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| US-20110230436-A1 | Uracyl Cyclopropyl Nucleotides | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010066699-A1 | URACYL CYCLOPROPYL NUCLEOTIDES | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | ALDH1A1 4139/4885GAA 342/4885MAPT 2970/4885 |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | ALDH1A1 2409/4885GAA 2441/4885MAPT 3511/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | ALDH1A1 2369/4885GAA 2400/4885MAPT 3529/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | ALDH1A1 2381/4885GAA 2461/4885MAPT 3584/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | ALDH1A1 2781/4885GAA 823/4885MAPT 3746/4885 |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | ALDH1A1 2524/4885GAA 2425/4885MAPT 3393/4885 |
| US-20110230436-A1 | Uracyl Cyclopropyl Nucleotides | NUDT1, PNP, RNGTT | ALDH1A1 1465/4885GAA 3240/4885MAPT 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.